GLP1R and polycystic ovary syndrome: This review also discusses the immunological implications of metabolic therapies - including metformin and glucagon-like peptide-1 receptor agonists - and the prospective role of targeted immunomodulation in selected immune-phenotypic PCOS subgroups.